Prognostic significance of nuisance bleeding in anticoagulated patients with atrial fibrillation

Circulation

Volumn 138, Issue 9, 2018, Pages 889-897

  O'Brien, Emily C ^a   Holmes, DaJuanicia N ^a   Thomas, Laine E ^a   Fonarow, Gregg C ^b   Allen, Larry A ^c   Gersh, Bernard J ^d   Kowey, Peter R ^e   Singer, Daniel E ^f   Ezekowitz, Michael D ^e   Naccarelli, Gerald V ^g   Ansell, Jack E ^h   Chan, Paul S ⁱ   Mahaffey, Kenneth W ^j   Go, Alan S ^k   Freeman, James V ^l   Reiffel, James A ^m   Peterson, Eric D ^a   Piccini, Jonathan P ^a   Hylek, Elaine M ⁿ  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d MAYO CLINIC   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^h DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

ⁱ UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k KAISER PERMANENTE   (United States)

^l YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m Division of Cardiology ^*  (United States)

ⁿ BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Anticoagulants; Atrial fibrillation; Hemorrhage; Risk assessment; Stroke

Indexed keywords

ADULT; ANEMIA; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CLINICAL OUTCOME; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEMOSTASIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY ANALYSIS; SKIN BRUISING; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE; AGED; BLOOD; BLOOD CLOTTING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPLICATION; DRUG EFFECT; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATIENT SATISFACTION; REGISTER; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ANTICOAGULANT AGENT;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; FEMALE; HEMORRHAGE; HUMANS; MALE; PATIENT SATISFACTION; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 85053859408     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.031354     Document Type: Article

References (32)

1. Stroke prevention in atrial fibrillation study. Final results. Circulation. 1991;84:527-539.
2. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992. doi: 10.1056/NEJMoa1107039
3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891. doi: 10.1056/NEJMoa1009638
4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RELY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151. doi: 10.1056/NEJMoa0905561
5. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: A report from the Swedish atrial fibrillation cohort study. Circulation. 2012;125:2298-2307. doi: 10.1161/CIRCULATIONAHA.111.055079
6. Arts DL, Visscher S, Opstelten W, Korevaar JC, Abu-Hanna A, van Weert HC. Frequency and risk factors for under- and over-treatment in stroke prevention for patients with non-valvular atrial fibrillation in general practice. PLoS One. 2013;8:e67806. doi: 10.1371/journal.pone.0067806
7. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med. 2010;123:638-645.e4. doi: 10.1016/j.amjmed.2009.11.025
8. O'Brien EC, Simon DN, Allen LA, Singer DE, Fonarow GC, Kowey PR, Thomas LE, Ezekowitz MD, Mahaffey KW, Chang P, Piccini JP, Peterson ED. Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014;168:487-494.
9. Gumbinger C, Holstein T, Stock C, Rizos T, Horstmann S, Veltkamp R. Reasons underlying non-adherence to and discontinuation of anticoagulation in secondary stroke prevention among patients with atrial fibrillation. Eur Neurol. 2015;73:184-191. doi: 10.1159/000371574
10. Altman R, Rivas AJ, Gonzalez CD. Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: Rescue of the template bleeding time in a single-center prospective study. Thromb J. 2012;10:3. doi: 10.1186/1477-9560-10-3
11. Rosenman MB, Baker L, Jing Y, Makenbaeva D, Meissner B, Simon TA, Wiederkehr D, Deitelzweig S. Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records. Curr Med Res Opin. 2012;28:1407-1414. doi: 10.1185/03007995.2012.708653
12. Roy P, Bonello L, Torguson R, de Labriolle A, Lemesle G, Slottow TL, Steinberg DH, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Lindsay J, Waksman R. Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drugeluting stent implantation. Am J Cardiol. 2008;102:1614-1617. doi: 10.1016/j.amjcard.2008.07.063
13. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P; European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15:625-651. doi: 10.1093/europace/eut083
14. Amin AP, Bachuwar A, Reid KJ, Chhatriwalla AK, Salisbury AC, Yeh RW, Kosiborod M, Wang TY, Alexander KP, Gosch K, Cohen DJ, Spertus JA, Bach RG. Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. J Am Coll Cardiol. 2013;61:2130-2138. doi: 10.1016/j.jacc.2013.02.044
15. Piccini JP, Fraulo ES, Ansell JE, Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Thomas LE, Kong MH, Lopes RD, Mills RM, Peterson ED. Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF. Am Heart J. 2011;162: 606-612.e1.
16. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-694. doi: 10.1111/j.1538-7836.2005.01204.x
17. Cano SJ, Lamping DL, Bamber L, Smith S. The Anti-Clot Treatment Scale (ACTS) in clinical trials: Cross-cultural validation in venous thromboembolism patients. Health Qual Life Outcomes. 2012;10:120. doi: 10.1186/1477-7525-10-120
18. Ngwa JS, Cabral HJ, Cheng DM, Pencina MJ, Gagnon DR, LaValley MP, Cupples LA. A comparison of time dependent Cox regression, pooled logistic regression and cross sectional pooling with simulations and an application to the Framingham Heart Study. BMC Med Res Methodol. 2016;16:148. doi: 10.1186/s12874-016-0248-6
19. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest. 2010;137:263-272. doi: 10.1378/chest.09-1584
20. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol. 2011;58:395-401. doi: 10.1016/j.jacc.2011.03.031
21. Gallagher AM, Rietbrock S, Plumb J, van Staa TP. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: Do the appropriate patients receive stroke prophylaxis?. J Thromb Haemost. 2008;6:1500-1506. doi: 10.1111/j.1538-7836.2008.03059.x
22. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689-2696. doi: 10.1161/CIRCULATIONAHA.106.653048
23. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3:624-631. doi: 10.1161/CIRCOUTCOMES.110.937680
24. Hsu JC, Maddox TM, Kennedy KF, Katz DF, Marzec LN, Lubitz SA, Gehi AK, Turakhia MP, Marcus GM. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: Insights from the NCDR PINNACLE Registry. JAMA Cardiol. 2016;1:55-62. doi: 10.1001/jamacardio.2015.0374
25. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, Singer DE. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141:745-752.
26. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319:1701-1707. doi: 10.1056/NEJM198812293192604
27. Donzé J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, Aujesky D. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med. 2012;125:773-778. doi: 10.1016/j.amjmed.2012.01.033
28. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159:677-685.
29. National Institute for Health and Care Excellence (NICE) guidelines. Atrial fibrillation: Management. 2014. Http://guidance.Nice.Org.Uk/cg180 Accessed April 12, 2018.
30. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747. doi: 10.1093/eurheartj/ehs253
31. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunsø J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost. 2011;106:739-749. doi: 10.1160/TH11-05-0364
32. Lahaye S, Regpala S, Lacombe S, Sharma M, Gibbens S, Ball D, Francis K. Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost. 2014;111:465-473. doi: 10.1160/TH13-05-0424